Literature DB >> 16504990

Normal neuropsychological development in children with congenital complete heart block who may or may not be exposed to high-dose dexamethasone in utero.

A Brucato1, M G Astori, R Cimaz, P Villa, M Li Destri, L Chimini, R Vaccari, M Muscarà, M Motta, A Tincani, F Neri, S Martinelli.   

Abstract

BACKGROUND: Antenatal and postnatal treatment with dexamethasone (DEX) may negatively affect the neuropsychological development in children. Maternal anti-Ro/Sjögren's syndrome A (SSA) antibodies may also be associated with learning disabilities in offspring.
OBJECTIVE: To assess neuropsychological development in babies exposed to very high dosages of DEX in utero, whose mothers were anti-Ro/SSA positive.
METHODS: 13 children with congenital complete heart block (CHB) (11 exposed and 2 not exposed to DEX) and 3 healthy siblings, all of anti-Ro/SSA-positive women, were evaluated. 11 preschool-aged children (5 boys) were assessed using Griffiths Mental Development Scales. 5 school-aged children (2 boys) were examined using Wechsler Intelligence Scale for Children-Revised to check IQ and reading tests to explore the existence of learning disabilities or dyslexia. None of the children had had major neonatal complications, although those with CHB had to be paced at different intervals from birth.
RESULTS: The children had been exposed in utero to a mean total dose of 186.6 mg DEX. IQ levels were always normal (mean IQ 105.1, standard deviation (SD) 9.5). Only one child had a learning disability, of borderline clinical significance, but this child had never been exposed to DEX.
CONCLUSION: No negative effects were found on the neuropsychological development in this cohort of children, even if they had been exposed to maternal anti-Ro/SSA antibodies and to very high dosages of DEX (much higher than those used to improve fetal lung maturity). These findings might be of interest in view of the large number of infants exposed in the past to repeated antenatal courses of steroids.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16504990      PMCID: PMC1798357          DOI: 10.1136/ard.2005.049866

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  23 in total

1.  The effects of repeated antenatal glucocorticoid therapy on the developing brain.

Authors:  N Modi; H Lewis; N Al-Naqeeb; M Ajayi-Obe; C J Doré; M Rutherford
Journal:  Pediatr Res       Date:  2001-11       Impact factor: 3.756

Review 2.  Antenatal glucocorticoids and programming of the developing CNS.

Authors:  S G Matthews
Journal:  Pediatr Res       Date:  2000-03       Impact factor: 3.756

3.  Primary Sjögren's syndrome--treatment of fetal incomplete atrioventricular block with dexamethasone.

Authors:  E Theander; A Brucato; S Gudmundsson; S Salomonsson; M Wahren-Herlenius; R Manthorpe
Journal:  J Rheumatol       Date:  2001-02       Impact factor: 4.666

4.  Pregnancy outcome in 100 women with autoimmune diseases and anti-Ro/SSA antibodies: a prospective controlled study.

Authors:  A Brucato; A Doria; M Frassi; G Castellino; F Franceschini; D Faden; M Pia Pisoni; L Solerte; M Muscarà; A Lojacono; M Motta; I Cavazzana; A Ghirardello; F Vescovi; V Tombini; R Cimaz; P F Gambari; P L Meroni; B Canesi; A Tincani
Journal:  Lupus       Date:  2002       Impact factor: 2.911

5.  Repeated prenatal corticosteroid administration delays astrocyte and capillary tight junction maturation in fetal sheep.

Authors:  W L Huang; C G Harper; S F Evans; J P Newnham; S A Dunlop
Journal:  Int J Dev Neurosci       Date:  2001-08       Impact factor: 2.457

Review 6.  Anti-SSA/Ro and anti-SSB/La antibody-mediated congenital heart block.

Authors:  N Costedoat-Chalumeau; S Georgin-Lavialle; Z Amoura; J C Piette
Journal:  Lupus       Date:  2005       Impact factor: 2.911

7.  Antenatal corticosteroids revisited: repeat courses.

Authors: 
Journal:  NIH Consens Statement       Date:  2000 Aug 17-18

8.  Comparison of treatment with fluorinated glucocorticoids to the natural history of autoantibody-associated congenital heart block: retrospective review of the research registry for neonatal lupus.

Authors:  S Saleeb; J Copel; D Friedman; J P Buyon
Journal:  Arthritis Rheum       Date:  1999-11

9.  Risk of congenital complete heart block in newborns of mothers with anti-Ro/SSA antibodies detected by counterimmunoelectrophoresis: a prospective study of 100 women.

Authors:  A Brucato; M Frassi; F Franceschini; R Cimaz; D Faden; M P Pisoni; M Muscarà; G Vignati; M Stramba-Badiale; L Catelli; A Lojacono; I Cavazzana; A Ghirardello; F Vescovi; P F Gambari; A Doria; P L Meroni; A Tincani
Journal:  Arthritis Rheum       Date:  2001-08

10.  Effect of single versus multiple courses of antenatal corticosteroids on maternal and neonatal outcome.

Authors:  S Abbasi; D Hirsch; J Davis; J Tolosa; N Stouffer; R Debbs; J S Gerdes
Journal:  Am J Obstet Gynecol       Date:  2000-05       Impact factor: 8.661

View more
  8 in total

Review 1.  Pregnancy outcomes in patients with autoimmune diseases and anti-Ro/SSA antibodies.

Authors:  Antonio Brucato; Rolando Cimaz; Roberto Caporali; Véronique Ramoni; Jill Buyon
Journal:  Clin Rev Allergy Immunol       Date:  2011-02       Impact factor: 8.667

2.  Outcome of prenatally diagnosed isolated congenital complete atrioventricular block treated with transplacental betamethasone or ritodrine therapy.

Authors:  Taiyu Hayashi; Masahide Kaneko; Ki-Sung Kim; Yoshihiko Eryu; Takahiro Shindo; Takayoshi Isoda; Atsuko Murashima; Yushi Ito; Haruhiko Sago
Journal:  Pediatr Cardiol       Date:  2008-07-26       Impact factor: 1.655

3.  Prospective evaluation of fetuses with autoimmune-associated congenital heart block followed in the PR Interval and Dexamethasone Evaluation (PRIDE) Study.

Authors:  Deborah M Friedman; Mimi Y Kim; Joshua A Copel; Carolina Llanos; Claudine Davis; Jill P Buyon
Journal:  Am J Cardiol       Date:  2009-03-04       Impact factor: 2.778

Review 4.  Cardiac manifestations of neonatal lupus erythematosus: guidelines to management, integrating clues from the bench and bedside.

Authors:  Jill P Buyon; Robert M Clancy; Deborah M Friedman
Journal:  Nat Clin Pract Rheumatol       Date:  2009-03

Review 5.  Atrioventricular block during fetal life.

Authors:  Lindsey E Hunter; John M Simpson
Journal:  J Saudi Heart Assoc       Date:  2014-07-10

Review 6.  Fetal cardiac arrhythmias: Current evidence.

Authors:  Nathalie Jeanne Bravo-Valenzuela; Luciane Alves Rocha; Luciano Marcondes Machado Nardozza; Edward Araujo Júnior
Journal:  Ann Pediatr Cardiol       Date:  2018 May-Aug

Review 7.  Use of antenatal fluorinated corticosteroids in management of congenital heart block: Systematic review and meta-analysis.

Authors:  Armia Michael; Ahmad A Radwan; Ahmed Kamel Ali; Ahmed Yassien Abd-Elkariem; Sherif A Shazly
Journal:  Eur J Obstet Gynecol Reprod Biol X       Date:  2019-06-16

8.  Outcome of Antibody-Mediated Fetal Heart Disease With Standardized Anti-Inflammatory Transplacental Treatment.

Authors:  Wadi Mawad; Lisa Hornberger; Bettina Cuneo; Marie-Josée Raboisson; Anita J Moon-Grady; Jane Lougheed; Karim Diab; Julia Parkman; Earl Silverman; Edgar Jaeggi
Journal:  J Am Heart Assoc       Date:  2022-01-08       Impact factor: 6.106

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.